Details of the Drug

General Information of Drug (ID: DMT2FDC)

Drug Name
Desipramine
Synonyms
Demethylimipramine; Desimipramine; Desimpramine; Desipramin; Desipramina; Desipraminum; Desmethylimipramine; Dezipramine; Dimethylimipramine; Methylaminopropyliminodibenzyl; Monodemethylimipramine; Norimipramine; Norpramine; Pentofran; Pertrofane; Sertofran; Desipramine Hcl; DMI 50475; DMI (pharmaceutical); Desipramina [INN-Spanish]; Desipramine (D4); Desipramine (INN); Desipramine [INN:BAN]; Desipraminum [INN-Latin]; Norpramin (TN); Pertofrane (TN); ZERO/006017; N-(3-Methylaminopropyl)iminobibenzyl; (3-(10H,11H-Dibenzo[b,f]azepin-5-yl)propyl)methylamine; 10, 11-Dihydro-N-methyl-5H-dibez[b,f]azepine-5-propanamine; 10,11-Dihydro-5-(3-methylaminopropyl)-5H-dibenz(b,f)azepine; 3-(10,11-DIHYDRO-5H-DIBENZO[B,F]AZEPIN-5-YL)-N-METHYLPROPAN-1-AMINE; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine; 5-(gamma-Methylaminopropyl)iminodibenzyl
Indication
Disease Entry ICD 11 Status REF
Attention deficit hyperactivity disorder 6A05.Z Approved [1], [2], [3]
Depression 6A70-6A7Z Approved [1], [2], [3]
Therapeutic Class
Antidepressants
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 266.4
Topological Polar Surface Area (xlogp) 4.9
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability
82.5% of drug becomes completely available to its intended biological destination(s) [5]
Clearance
The drug present in the plasma can be removed from the body at the rate of 11 mL/min/kg [6]
Elimination
2% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 7 - 60 hours [6]
Metabolism
The drug is metabolized via the liver [7]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 16.08816 micromolar/kg/day [8]
Unbound Fraction
The unbound fraction of drug in plasma is 0.16% [6]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 15 L/kg [6]
Chemical Identifiers
Formula
C18H22N2
IUPAC Name
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine
Canonical SMILES
CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31
InChI
InChI=1S/C18H22N2/c1-19-13-6-14-20-17-9-4-2-7-15(17)11-12-16-8-3-5-10-18(16)20/h2-5,7-10,19H,6,11-14H2,1H3
InChIKey
HCYAFALTSJYZDH-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2995
ChEBI ID
CHEBI:47781
CAS Number
50-47-5
DrugBank ID
DB01151
TTD ID
D01UTL
VARIDT ID
DR00501
INTEDE ID
DR0436
ACDINA ID
D00179

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Norepinephrine transporter (NET) TTAWNKZ SC6A2_HUMAN Inhibitor [9]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [10]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [11]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [12]
Cytochrome P450 2D6 (CYP2D6)
Main DME 		DECB0K3 CP2D6_HUMAN Substrate [13]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [14]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [15]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Substrate [16]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Attention deficit hyperactivity disorder
ICD Disease Classification 6A05.Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Norepinephrine transporter (NET) DTT SLC6A2 7.05E-01 7.02E-03 0.07
P-glycoprotein 1 (ABCB1) DTP P-GP 7.83E-01 4.69E-02 1.89E-01
Organic cation transporter 1 (SLC22A1) DTP SLC22A1 5.15E-01 1.61E-02 7.93E-02
Cytochrome P450 2B6 (CYP2B6) DME CYP2B6 5.79E-01 -1.30E-02 -9.78E-02
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 8.68E-01 3.64E-02 2.72E-01
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 7.66E-01 9.19E-03 4.88E-02
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 5.64E-01 2.36E-02 1.75E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 6.06E-01 -2.42E-02 -1.64E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Desipramine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Major Additive serotonergic effects by the combination of Desipramine and Methylene blue. Acquired methaemoglobinaemia [3A93] [83]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Desipramine and Ivosidenib. Acute myeloid leukaemia [2A60] [84]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Desipramine and Midostaurin. Acute myeloid leukaemia [2A60] [85]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Desipramine and Idarubicin. Acute myeloid leukaemia [2A60] [85]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Desipramine and Arn-509. Acute myeloid leukaemia [2A60] [86]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Desipramine and Gilteritinib. Acute myeloid leukaemia [2A60] [87]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Desipramine and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [88]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Desipramine and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [88]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Desipramine and Ivabradine. Angina pectoris [BA40] [86]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Desipramine and Bepridil. Angina pectoris [BA40] [89]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Desipramine and Dronedarone. Angina pectoris [BA40] [85]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Desipramine and Cilostazol. Arterial occlusive disease [BD40] [85]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Desipramine and Posaconazole. Aspergillosis [1F20] [85]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Desipramine and Clarithromycin. Bacterial infection [1A00-1C4Z] [85]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Desipramine and Sparfloxacin. Bacterial infection [1A00-1C4Z] [90]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Desipramine and Gemifloxacin. Bacterial infection [1A00-1C4Z] [90]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Desipramine and Retigabine. Behcet disease [4A62] [85]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Desipramine and Cariprazine. Bipolar disorder [6A60] [91]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Desipramine and Eribulin. Breast cancer [2C60-2C6Y] [85]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Desipramine and Lapatinib. Breast cancer [2C60-2C6Y] [85]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Desipramine and Bosutinib. Breast cancer [2C60-2C6Y] [86]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Desipramine when combined with Acetylcholine. Cataract [9B10] [92]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Desipramine and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [93]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Desipramine and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [94]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Desipramine and Revefenacin. Chronic obstructive pulmonary disease [CA22] [94]
Dihydrocodeine DMB0FWL Moderate Additive CNS depression effects by the combination of Desipramine and Dihydrocodeine. Chronic pain [MG30] [95]
Levomilnacipran DMV26S8 Major Additive serotonergic effects by the combination of Desipramine and Levomilnacipran. Chronic pain [MG30] [96]
Mestranol DMG3F94 Minor Decreased metabolism of Desipramine caused by Mestranol. Contraceptive management [QA21] [97]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Desipramine and Halothane. Corneal disease [9A76-9A78] [85]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Desipramine and Probucol. Coronary atherosclerosis [BA80] [85]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Desipramine and Pasireotide. Cushing syndrome [5A70] [85]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Desipramine and Osilodrostat. Cushing syndrome [5A70] [86]
Vilazodone DM4LECQ Major Additive serotonergic effects by the combination of Desipramine and Vilazodone. Depression [6A70-6A7Z] [96]
Vortioxetine DM6F1PU Major Additive serotonergic effects by the combination of Desipramine and Vortioxetine. Depression [6A70-6A7Z] [96]
Isocarboxazid DMAF1NB Major Additive serotonergic effects by the combination of Desipramine and Isocarboxazid. Depression [6A70-6A7Z] [83]
Milnacipran DMBFE74 Major Additive serotonergic effects by the combination of Desipramine and Milnacipran. Depression [6A70-6A7Z] [96]
Desvenlafaxine DMHD4PE Major Additive serotonergic effects by the combination of Desipramine and Desvenlafaxine. Depression [6A70-6A7Z] [96]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Desipramine and OPC-34712. Depression [6A70-6A7Z] [91]
Clomipramine DMINRKW Moderate Additive anticholinergic effects by the combination of Desipramine and Clomipramine. Depression [6A70-6A7Z] [91]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Desipramine and Mepenzolate. Digestive system disease [DE2Z] [91]
5-hydroxy-L-tryptophan DMDWZGJ Major Additive serotonergic effects by the combination of Desipramine and 5-hydroxy-L-tryptophan. Discovery agent [N.A.] [98]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Desipramine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [85]
Deutetrabenazine DMUPFLI Moderate Additive CNS depression effects by the combination of Desipramine and Deutetrabenazine. Dystonic disorder [8A02] [99]
Ingrezza DMVPLNC Moderate Additive CNS depression effects by the combination of Desipramine and Ingrezza. Dystonic disorder [8A02] [100]
Fosphenytoin DMOX3LB Moderate Decreased metabolism of Desipramine caused by Fosphenytoin mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [101]
Solifenacin DMG592Q Moderate Additive anticholinergic effects by the combination of Desipramine and Solifenacin. Functional bladder disorder [GC50] [91]
Mirabegron DMS1GYT Moderate Decreased metabolism of Desipramine caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [102]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Desipramine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [85]
Boceprevir DMBSHMF Moderate Decreased metabolism of Desipramine caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [103]
Telaprevir DMMRV29 Moderate Decreased metabolism of Desipramine caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [103]
Procarbazine DMIK367 Major Additive serotonergic effects by the combination of Desipramine and Procarbazine. Hodgkin lymphoma [2B30] [83]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Desipramine and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [104]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Desipramine caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [105]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Desipramine and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [106]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Desipramine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [85]
Givosiran DM5PFIJ Moderate Decreased metabolism of Desipramine caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [107]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Desipramine and Belladonna. Infectious gastroenteritis/colitis [1A40] [91]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Desipramine and ITI-007. Insomnia [7A00-7A0Z] [91]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Desipramine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [86]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Desipramine and Crizotinib. Lung cancer [2C25] [108]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Desipramine and Ceritinib. Lung cancer [2C25] [85]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Desipramine caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [109]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Desipramine and Selpercatinib. Lung cancer [2C25] [86]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Desipramine and Lumefantrine. Malaria [1F40-1F45] [110]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Desipramine and Hydroxychloroquine. Malaria [1F40-1F45] [111]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Desipramine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [86]
IPI-145 DMWA24P Moderate Decreased metabolism of Desipramine caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [112]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Desipramine and Arsenic trioxide. Mature B-cell lymphoma [2A85] [113]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Desipramine and Vemurafenib. Melanoma [2C30] [85]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Desipramine and LGX818. Melanoma [2C30] [114]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Desipramine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [115]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Desipramine and Flibanserin. Mood disorder [6A60-6E23] [116]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Desipramine and Panobinostat. Multiple myeloma [2A83] [117]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Desipramine and Siponimod. Multiple sclerosis [8A40] [110]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Desipramine and Fingolimod. Multiple sclerosis [8A40] [85]
Ozanimod DMT6AM2 Major Additive serotonergic effects by the combination of Desipramine and Ozanimod. Multiple sclerosis [8A40] [118]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Desipramine and Romidepsin. Mycosis fungoides [2B01] [85]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Desipramine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [86]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Desipramine and Nilotinib. Myeloproliferative neoplasm [2A20] [85]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Desipramine and Dasatinib. Myeloproliferative neoplasm [2A20] [119]
Phenindamine DMDTC7R Moderate Additive anticholinergic effects by the combination of Desipramine and Phenindamine. Nasopharyngitis [CA00] [91]
Rolapitant DM8XP26 Moderate Decreased metabolism of Desipramine caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [120]
Cyclizine DM9G7BS Moderate Additive anticholinergic effects by the combination of Desipramine and Cyclizine. Nausea/vomiting [MD90] [91]
Bupropion DM5PCS7 Major Decreased metabolism of Desipramine caused by Bupropion mediated inhibition of CYP450 enzyme. Nicotine use disorder [6C4A] [85]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Desipramine and Entrectinib. Non-small cell lung cancer [2C25] [110]
Lorcaserin DMG6OYJ Major Additive serotonergic effects by the combination of Desipramine and Lorcaserin. Obesity [5B80-5B81] [121]
Dexfenfluramine DMJ7YDS Major Additive serotonergic effects by the combination of Desipramine and Dexfenfluramine. Obesity [5B80-5B81] [96]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Desipramine and Levomethadyl Acetate. Opioid use disorder [6C43] [86]
Lofexidine DM1WXA6 Moderate Additive CNS depression effects by the combination of Desipramine and Lofexidine. Opioid use disorder [6C43] [86]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Desipramine and Rucaparib. Ovarian cancer [2C73] [85]
Oxymorphone DM65AGJ Moderate Additive serotonergic effects by the combination of Desipramine and Oxymorphone. Pain [MG30-MG3Z] [95]
Dezocine DMJDB0Y Moderate Additive serotonergic effects by the combination of Desipramine and Dezocine. Pain [MG30-MG3Z] [95]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Desipramine and Triclabendazole. Parasitic worm infestation [1F90] [85]
Safinamide DM0YWJC Major Additive serotonergic effects by the combination of Desipramine and Safinamide. Parkinsonism [8A00] [118]
Rasagiline DM3WKQ4 Major Additive serotonergic effects by the combination of Desipramine and Rasagiline. Parkinsonism [8A00] [83]
Levodopa DMN3E57 Minor Altered absorption of Desipramine due to GI dynamics variation caused by Levodopa. Parkinsonism [8A00] [122]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Desipramine and Pimavanserin. Parkinsonism [8A00] [123]
Orphenadrine DMW542E Moderate Additive anticholinergic effects by the combination of Desipramine and Orphenadrine. Parkinsonism [8A00] [91]
Abametapir DM2RX0I Moderate Decreased metabolism of Desipramine caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [124]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Desipramine and Methylscopolamine. Peptic ulcer [DA61] [91]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Desipramine and Macimorelin. Pituitary gland disorder [5A60-5A61] [125]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Desipramine and Lefamulin. Pneumonia [CA40] [126]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Desipramine and Degarelix. Prostate cancer [2C82] [86]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Desipramine caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [127]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Desipramine and Enzalutamide. Prostate cancer [2C82] [86]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Desipramine and Relugolix. Prostate cancer [2C82] [86]
Levomepromazine DMIKFEL Moderate Increased plasma concentrations of Desipramine and Levomepromazine due to competitive inhibition of the same metabolic pathway. Psychotic disorder [6A20-6A25] [128]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Desipramine and Quetiapine. Schizophrenia [6A20] [85]
Aripiprazole DM3NUMH Moderate Additive anticholinergic effects by the combination of Desipramine and Aripiprazole. Schizophrenia [6A20] [91]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Desipramine and Iloperidone. Schizophrenia [6A20] [85]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Desipramine and Paliperidone. Schizophrenia [6A20] [85]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Desipramine and Molindone. Schizophrenia [6A20] [91]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Desipramine and Thiothixene. Schizophrenia [6A20] [91]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Desipramine and Amisulpride. Schizophrenia [6A20] [129]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Desipramine and Asenapine. Schizophrenia [6A20] [85]
Armodafinil DMGB035 Moderate Decreased metabolism of Desipramine caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [110]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Desipramine and LEE011. Solid tumour/cancer [2A00-2F9Z] [85]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Desipramine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [85]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Desipramine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [86]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Desipramine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [85]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Desipramine and Lenvatinib. Thyroid cancer [2D10] [85]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Desipramine and Cabozantinib. Thyroid cancer [2D10] [86]
Trimeprazine DMEMV9D Moderate Increased plasma concentrations of Desipramine and Trimeprazine due to competitive inhibition of the same metabolic pathway. Vasomotor/allergic rhinitis [CA08] [130]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Desipramine and Acrivastine. Vasomotor/allergic rhinitis [CA08] [91]
Propafenone DMPIBJK Moderate Decreased metabolism of Desipramine caused by Propafenone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [131]
Flecainide DMSQDLE Moderate Decreased metabolism of Desipramine caused by Flecainide mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [131]
⏷ Show the Full List of 126 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Calcium carbonate E00198 10112 Binding agent; Buffering agent; Diluent; Opacifying agent
D&C red no. 27 E00381 83511 Colorant
D&C red no. 30 E00456 3000709 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS E00309 24671 Colorant
Sodium benzoate E00432 517055 Antimicrobial preservative; lubricant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF E00255 17730 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium E00625 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 24 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Desipramine 10 mg tablet 10 mg Oral Tablet Oral
Desipramine 100 mg tablet 100 mg Oral Tablet Oral
Desipramine 150 mg tablet 150 mg Oral Tablet Oral
Desipramine 25 mg tablet 25 mg Oral Tablet Oral
Desipramine 50 mg tablet 50 mg Oral Tablet Oral
Desipramine 75 mg tablet 75 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2399).
2 Emerging treatments for depression. Expert Opin Pharmacother. 2006 Dec;7(17):2323-39.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 BDDCS applied to over 900 drugs
5 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
8 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9 Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
10 Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
11 A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26.
12 Variability in metabolism of imipramine and desipramine using urinary excretion data. J Anal Toxicol. 2014 Jul-Aug;38(6):368-74.
13 Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol. 1996;51(1):73-8.
14 Eight inhibitory monoclonal antibodies define the role of individual P-450s in human liver microsomal diazepam, 7-ethoxycoumarin, and imipramine metabolism. Drug Metab Dispos. 1999 Jan;27(1):102-9.
15 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
16 Drugs that may have potential CYP2B6 interactions.
17 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
18 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
19 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
20 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
21 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
22 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
23 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
24 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
25 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
26 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
27 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
28 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
29 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
30 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
31 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
32 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
33 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
34 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
35 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
36 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
37 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
38 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
39 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
40 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
41 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
42 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
43 Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
44 Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
45 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
46 Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
47 Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
48 Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
49 PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
50 Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
51 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
52 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
53 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
54 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
55 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
56 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
57 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
58 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
59 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
60 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
61 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
62 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
63 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
64 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
65 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
66 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
67 Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
68 Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
69 Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
70 Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
71 Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
72 Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
73 Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
74 Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
75 Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
76 Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8.
77 Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
78 Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
79 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
80 Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90.
81 Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
82 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
83 Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
84 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
85 Canadian Pharmacists Association.
86 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
87 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
88 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
89 Hollingshead LM, Faulds D, Fitton A "Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris." Drugs 44 (1992): 835-57. [PMID: 1280569]
90 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
91 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
92 Multum Information Services, Inc. Expert Review Panel.
93 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
94 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
95 Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
96 Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
97 Edelbroek PM, Zitman FG, Knoppert-van der Klein EA, van Putten PM, de Wolff FA "Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women." Clin Chim Acta 165 (1987): 177-87. [PMID: 3652444]
98 Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50. [PMID: 1968472]
99 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
100 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
101 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
102 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
103 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
104 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
105 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
106 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
107 Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
108 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
109 Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
110 Cerner Multum, Inc. "Australian Product Information.".
111 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
112 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
113 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
114 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
115 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
116 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
117 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
118 Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
119 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
120 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
121 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
122 Morgan JP, Rivera-Calimlim L, Messiha F, Sundaresan PR, Trabert N "Imipramine-mediated interference with levodopa absorption from the gastrointestinal tract in man." Neurology 25 (1975): 1029-34. [PMID: 1237820]
123 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
124 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
125 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
126 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
127 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
128 Bock JL, Nelson JC, Gray S, Jatlow PI "Desipramine hydroxylation: variability and effect of antipsychotic drugs." Clin Pharmacol Ther 33 (1983): 322-8. [PMID: 6130865]
129 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
130 Lee BS "Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs." J Clin Psychiatry 47 (1986): 571. [PMID: 3771507]
131 Katz MR "Raised serum levels of desipramine with the antiarrhythmic propafenone ." J Clin Psychiatry 52 (1991): 432-3. [PMID: 1938981]